Simsen Diagnostics

𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲: 𝐔𝐧𝐥𝐞𝐚𝐬𝐡𝐢𝐧𝐠 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐎𝐧𝐞 𝐁𝐥𝐨𝐨𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐚𝐭 𝐚 𝐓𝐢𝐦𝐞 Imagine a world where cancer treatment is precisely tailored to each patient, guided by real-time insights from a simple blood draw. At Simsen Diagnostics, we're making that vision a reality. 🔬We're harnessing the power of circulating tumor DNA (ctDNA) analysis to unlock a wealth of information hidden within a single drop of blood. This revolutionary technology allows us to: • 𝐃𝐞𝐭𝐞𝐜𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 𝐞𝐚𝐫𝐥𝐢𝐞𝐫, 𝐢𝐦𝐩𝐫𝐨𝐯𝐢𝐧𝐠 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬. • 𝐌𝐨𝐧𝐢𝐭𝐨𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞 𝐰𝐢𝐭𝐡 𝐮𝐧𝐩𝐚𝐫𝐚𝐥𝐥𝐞𝐥𝐞𝐝 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧. • 𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐲 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐞𝐚𝐜𝐡 𝐢𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥. 𝐎𝐮𝐫 𝐦𝐢𝐬𝐬𝐢𝐨𝐧 𝐢𝐬 𝐜𝐥𝐞𝐚𝐫: 𝐔𝐧𝐥𝐞𝐚𝐬𝐡𝐢𝐧𝐠 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐎𝐧𝐞 𝐁𝐥𝐨𝐨𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐚𝐭 𝐚 𝐓𝐢𝐦𝐞. 📈 𝐉𝐨𝐢𝐧 𝐭𝐡𝐞 𝐌𝐨𝐯𝐞𝐦𝐞𝐧𝐭: Simsen Diagnostics is committed to pushing the boundaries of what's possible in cancer diagnostics. By harnessing the power of ctDNA, we aim to empower oncology innovators with the knowledge and tools needed to revolutionize cancer care. 👥 𝐋𝐞𝐭'𝐬 𝐂𝐨𝐧𝐧𝐞𝐜𝐭: Are you ready to stay ahead of the curve and be a part of this transformation? Follow us for the latest insights and join the conversation on how ctDNA is reshaping the future of oncology. Like, comment, or share if you're as excited about this game-changing technology as we are! 🔗 SimsenDiagnostics.com #OncologyInnovation #ctDNA #CancerDiagnostics #PrecisionMedicine #SimsenDiagnostics #HealthcareRevolution #OncologyPharma #ThoughtLeadership #CancerResearch

Tumor-informed vs. tumor-naïve ctDNA detection An important axis for classifying ctDNA assays is whether they are tumor-informed or tumor-naïve. Tumor-informed assays are tailor-made designs based on the genetic information provided by a tumor biopsy. Tumor-naïve assays are typically fixed panels containing primers or probes targeting highly recurrent mutations present in specific tumor types. Tumor-informed assays have orders-of-magnitude greater sensitivity than tumor-naive multigene panels. A tumor-naïve panel may not cover variants found in some patients, especially for cancer types with a highly heterogeneous tumor mutational landscape and few recurrent mutations between tumors. By contrast, prior knowledge from assessment of variants in tumor tissue allows tracking of a greater number of high-quality variants, enhancing sensitivity. A significant challenge to maintaining the specificity of ctDNA testing is confounding by clonal hematopoiesis of indeterminate potential (CHIP). Recent studies have reported that 14% of patients with early-stage lung cancer and 25% of patients with late-stage solid tumors harbor CHIP mutations. Misclassifying CHIP variants as ctDNA variants may reduce specificity for MRD detection. Approaches to address this misclassification include sequencing paired peripheral blood cells for in silico filtering of variants common to peripheral blood cells and ctDNA and using tumor-informed methods to identify clonal tumor variants. To learn more: Go to Simsen Diagnostics or simsendiagnostics.com #CHIP #ctDNA #tumor #simsendiagnostics #cancer #diagnostics

🧬 Tumor-Informed vs. Tumor-Naïve ctDNA Detection: What Pharma Executives Need to Know 🧬 Navigating the landscape of circulating tumor DNA (ctDNA) detection is crucial for advancing cancer diagnostics and treatment. Here’s a quick rundown: Types of Assays: Tumor-Informed Assays: These are customized based on a patient's tumor biopsy. They require sequencing the primary tumor, offering high sensitivity by detecting multiple high-quality, tumor-specific mutations. Tumor-Naïve Assays: Utilize fixed panels targeting common mutations in specific cancers (e.g., breast, colon). They are less sensitive, typically identifying 2-5 variants per patient. Why Sensitivity and Specificity Matter: Tumor-informed methods are significantly more sensitive than tumor-naïve methods. Tumor-naïve panels might miss some patient-specific variants, especially in cancers with highly diverse mutations, increasing the risk of false positives which can lead to unnecessary treatments. Challenges which Simsen® Personal Addresses: Clonal Hematopoiesis of Indeterminate Potential (CHIP): CHIP mutations from blood cells can be mistaken for ctDNA, reducing test specificity. Solutions: Sequencing paired blood cells and employing tumor-informed methods to filter out CHIP variants. Comparative Sensitivity: Traditional qPCR: 1-5% sensitivity, detects 1 marker. Fixed NGS Panel: >0.5% sensitivity, detects 2-5 markers. Personalized NGS: <0.01% sensitivity, detects 20-50+ markers. Understanding these differences helps in selecting the right ctDNA assay, balancing sensitivity, specificity, and the impact on clinical decisions. #Pharma #Oncology #ctDNA #CancerDiagnostics #MedicalInnovation #Healthcare #SimsenPersonal #SimsenDiagnostics Feel free to share your insights or ask questions in the comments below! 👇

As we approach summer and vacations (at least for some of us in the office and most industry people here in Sweden), we wanted to take a moment to look back at the first half of the year. While working day to day and constantly striving for the next step, higher levels, more customers, more progress, more, more, more, it is sometimes easy to forget what you’ve achieved so far. Summer break is the perfect time to reflect, celebrate our milestones, and recharge for the upcoming year. Take a closer look at what we've accomplished and learned in our mid-year summary on our website. (link in the comments) #2024Recap #Innovation #Cancer #ctDNA #Growth #Biotech #SummerBreak

The quote from the British journalist and broadcaster, best known for his writing about his fight against cancer, reminds us that there is always hope. While cancer is a challenging diagnosis, it does not have to define one's entire life. We firmly believe that cancer is a challenge to be faced and overcome, not a final chapter. We strive to make meaningful contributions toward that goal.

MAJOR News 📣 We are extremely excited to announce our collaboration with Orion Corporation, Finland's leading pharmaceutical company, and a big global industry player. This significant step enables us to further expand in the Nordics and contribute to the important studies Orion is leading. Read the full press release in the comments. 👇

It's almost time to close our laptops and leave the office for the Swedish Midsummer celebration. 🎊 The time when the sun stays up late and Swedes transform into little dancing frogs... If you've experienced it, you know exactly what we mean. 🐸 The entire Simsen Diagnostics team wishes you a wonderful Midsummer! 🌸 ✨

Detecting the smallest amounts can make the biggest difference. Detecting cancer relapse or remaining disease early enough can significantly improve patient outcomes. At Simsen we might focus on small things but aim to make a big difference. #ctDNA #cancer #cancercare

Employee Highlight: Meet Stefan! 😎 Have you met Stefan? If not, now is the perfect time to get to know him. Stefan Filges, our Chief Technology Officer and the very first employee of Simsen Diagnostics, is an experienced bioinformatician with a Ph.D. in ultrasensitive sequencing. He played a crucial role as a co-author in the original publication of SiMSen-Seq, the groundbreaking technology that forms the basis of our solutions. This work was published in Nature Protocols. Recently, another study that Stefan contributed to was published. If you're curious about what he worked on during his Ph.D. besides SiMSen-Seq, take a look at the linked study in the comments below. Stefan is the one we always ask for advice. Try it yourself; he always has an answer. 😉

Ultrasensitivity - what is it? When we describe our technology as ultrasensitive, it indicates our capability to detect extremely small amounts of cancer-related material, particularly circulating tumor DNA (ctDNA). To illustrate, think about how hard it is to find one tiny grain of sand on a huge beach. Our technology works like a precise magnet, carefully picking out these tiny bits from a massive amount of genetic information. And why is this ultrasensitivity so important?  Well, it enables: 1️⃣ Identifying Cancer Relapse: Catching cancer's return at the earliest stage.   2️⃣ Monitoring Minimal Residual Disease (MRD): Detecting small amounts of remaining cancer cells post-treatment.  3️⃣ Tracking Treatment Response: Assessing therapy effectiveness by detecting changes in ctDNA levels. #cancer #cancermonitoring #ctDNA